Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Lipotec SA | 39 |
| 2 | L'Oréal SA | 37 |
| 3 | Symrise AG | 32 |
| 4 | Pfizer Inc | 31 |
| 5 | Pfizer Corp SRL | 29 |
| 6 | Patheon Softgels Inc | 27 |
| 7 | Procter and Gamble Co | 23 |
| 8 | Fidia Farmaceutici SpA | 22 |
| 9 | DIC Corp | 21 |
| 10 | Fidia SpA | 21 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 565 |
| 2 | A61P | Therapeutic activity (drug indications) | 368 |
| 3 | A61Q | Cosmetics, personal care | 224 |
| 4 | C07J | 159 | |
| 5 | C08L | Polymer compositions (blends) | 69 |
| 6 | A61L | Sterilising / disinfecting materials | 59 |
| 7 | G01N | Investigating / analysing materials | 48 |
| 8 | A01N | Preservation of bodies; biocides; pest repellents | 41 |
| 9 | C08B | 41 | |
| 10 | A23L | Foods and beverages (general) | 36 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis | 1986 | Medical Research Foundation of Oregon | 77 |
| Smilagenin and its use | 2001 | PHYTOPHARM PLC | 38 |
| COMPOSITION COMPRISING SARSASAPOGENIN | 2008 | Sederma SA | 22 |
| Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside | 1985 | Medical Research Foundation of Oregon | 16 |
| Process for the preparation of tigogenin beta-cellobioside | 1990 | Pfizer Corp Belgium | 13 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Phytochemical Studies and Bioactivities | 2 |
| 2 | Bee Products Chemical Analysis | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Bertrand Liagre | Université de Limoges | 5 |
| 2 | Cécile Corbière | Université de Limoges | 4 |
| 3 | Jean‐Louis Beneytout | Université de Limoges | 3 |
| 4 | Guoping Cai | University Town of Shenzhen | 2 |
| 5 | Hiroyuki Tanaka | Kyushu University | 2 |
| 6 | Hua Zhou | University Town of Shenzhen | 2 |
| 7 | Naili Wang | Shenyang Pharmaceutical University | 2 |
| 8 | Pascale Vergne‐Salle | Hôpital Dupuytren | 2 |
| 9 | Scott W. Nelson | Iowa State University | 2 |
| 10 | Xi Yang | Air Force Medical University | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane | 2008 | 114 | Rheumatoid Arthritis Research and Therapies |
| Structure–function relationship for saponin effects on cell cycle arrest and apoptosis in the human 1547 osteosarcoma cells: a molecular modelling approach of natural molecules structurally close to diosgenin | 2004 | 97 | Natural product bioactivities and synthesis |
| A novel glucosyltransferase involved in steroid saponin biosynthesis in Solanum aculeatissimum | 2005 | 81 | Natural product bioactivities and synthesis |
| UDP-GLUCURONOSYLTRANSFERASE 1A4 POLYMORPHISMS IN A JAPANESE POPULATION AND KINETICS OF CLOZAPINE GLUCURONIDATION | 2005 | 76 | Pharmacogenetics and Drug Metabolism |
| In vivo anthelmintic activity of an aqueous extract from sisal waste (Agave sisalana Perr.) against gastrointestinal nematodes in goats | 2010 | 49 | Parasites and Host Interactions |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular structure of Parigenin?
Which companies hold the most patents related to Parigenin?
What are the primary patent application areas for Parigenin-related inventions?
Who are the leading researchers publishing on Parigenin?
What patents have had the greatest impact on the field based on citation counts?